|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1016 W Jackson Blvd |
Address2 | #1073 |
| City | Chicago |
State | IL |
Zip Code | 60607 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400348610-12
|
||||||||
|
6. House ID# 403510000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Paul Melmeyer |
Date | 4/12/2024 4:20:15 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocated for the protection of the Medicaid program to the White House and Congress
Supported enhanced funding for NCATS
Supported the nomination of Duchenne muscular dystrophy in front of HRSAs ACHDNC
Supported the Protecting Healthcare for All Patients Act
Worked on the introduction of the ALS Better Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Supported the Right Drug, Right Dose Act
Supported robust appropriations for the newborn screening program.
Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings
Supported funding of ALS research, expanded access, and more
Advocated for the passage of the RARE ACT
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Urged CMS to tread carefully with the Medicaid unwinding
Advocated for the elimination of junk plans to Congress and supported the Administrations proposal
Endorsed the Telehealth Benefit Expansion for Workers Act
Supported the Medicare Orthotics & Prosthetics Patient-Centered Care Act
Continued efforts to reintroduce the Newborn Screening Saves Lives Reauthorization Act
Supported the NIH Clinical Trial Diversity Act
Provided comments to the House Ways and Means Committee on the No Surprises Act
Joined coalition comments on ACA-plan eligibility for DACA participants
Provided comments to the FDA on individualized cell and gene therapy products
Supported changes to the Inflation Reduction Act pertaining to rare disease therapies and timelines for negotiation
Supported the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AVI
16. Specific lobbying issues
Supported accessible air travel reforms to be included in the FAA Reauthorization
Supported the MOBILE Act, legislation to make air travel more accessible
Supported the Air Carrier Access Amendments Act, legislation to make air travel more accessible
Supported the EVAC Act, legislation to ensure evacuations of airplanes considers those with disabilities
Supported accessibility provisions within the Securing Growth and Robust Leadership in American Aviation Act of 2023
Advocated for stronger protections of individuals with disabilities when engaging with TSA
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Aviation Administration (FAA), Transportation - Dept of (DOT), Transportation Security Administration (TSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Supported enhanced funding for NCATS, NIAMS, and the entire NIH
Supported robust appropriations for the newborn screening program.
Supported funding of ALS research, expanded access, and more
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Supported enhanced funding for NCATS, NIAMS, and the entire NIH
Supported the nomination of Duchenne muscular dystrophy in front of HRSAs ACHDNC
Worked on the introduction of the ALS Better Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Supported the Right Drug, Right Dose Act
Supported robust appropriations for the newborn screening program.
Supported funding of ALS research, expanded access, and more
Advocated for the passage of the RARE ACT
Continued efforts to reintroduce the Newborn Screening Saves Lives Reauthorization Act
Submitted comments to the FDA on individualized gene therapies
Supported the inclusion of certain provisions within the Pandemic and All-Hazards Preparedness Act reauthorization
Endorsed the NIH Clinical Trial Diversity Act
Provided comments to the FDA on their proposed rule on lab-developed tests
Supported the Ensuring Patient Access to Critical Breakthrough Products Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for the protection of the Medicaid program to the White House and Congress
Supported the Protecting Healthcare for All Patients Act
Worked on the introduction of the ALS Better Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Supported the Right Drug, Right Dose Act
Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Urged CMS to tread carefully with the Medicaid unwinding
Provided comments to the House Ways and Means Committee on Medicaid unwinding
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for the protection of the Medicaid program to the White House and Congress
Supported the Protecting Healthcare for All Patients Act
Worked on the introduction of the ALS Better Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Supported the Right Drug, Right Dose Act
Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Urged CMS to tread carefully with the Medicaid unwinding
Advocated for the elimination of junk plans to Congress and supported the Administrations proposal
Supported the Ensuring Patient Access to Critical Breakthrough Products Act
Joined a letter to President Biden on DACA eligibility for ACA plans
Submitted comments to the House Ways and Means Committee on the No Surprises Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Supported the Protecting Healthcare for All Patients Act
Worked on the introduction of the ALS Better Care Act
Supported the introduction of legislation that increases access to genetic testing and genetic counselors
Supported the Right Drug, Right Dose Act
Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings
Supported funding of ALS research, expanded access, and more
Advocated for provisions addressing problems within the pharmacy benefit manager industry
Advocated for the elimination of junk plans to Congress and supported the Administrations proposal
Supported changes to the Inflation Reduction Act pertaining to rare disease therapeutic eligibility for Medicare negotiation
Provided comments to the House Ways and Means Committee on the No Surprises Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
Supported accessible air travel reforms to be included in the FAA Reauthorization
Supported the MOBILE Act, legislation to make air travel more accessible
Supported the Air Carrier Access Amendments Act, legislation to make air travel more accessible
Supported the EVAC Act, legislation to ensure evacuations of airplanes considers those with disabilities
Supported a final rule intended to make lavatories on single aisle aircrafts accessible.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Federal Aviation Administration (FAA), U.S. HOUSE OF REPRESENTATIVES, Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Supported the RISE Act
Supported the Full Funding is the Right IDEA Act
17. House(s) of Congress and Federal agencies Check if None
Education - Dept of, U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Lewis |
|
|
|
Paul |
Melmeyer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
Joined comments to the DOJ on Proposed Rule on Web Accessibility
17. House(s) of Congress and Federal agencies Check if None
Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |